Pipeline

At present our R&D portfolio includes nine first-in-class and BioBetters medicines based on three technological platforms – PolyXen, Histone and Gemacell.

Development of Innovative Technologies for the SynBio Project

Currently under Development

PolyXEN:

• "Product A"- for treatment and/or prevention of anemia; contains a conjugate of EPO and polysialic acid as the active ingredient.
  Code:  SYN 20070131RU

• "Product B" – for treatment of febrile neutropenia; contains a conjugate of G-CSF and polysialic acid as the active ingredient.
  Code:  SYN 20111504RU

• "Product C" – for treatment and/or prevention of diabetes mellitus and Alzheimer's disease; contains a conjugate of insulin and polysialic acid as the active ingredient.
  Code: SYN20090510RU
  Code: SYN20090110RU

• "Product D" – for treatment of chronic hepatitis C; contains a conjugate of interferon alfa-2b and polysialic acid as the active ingredient.
  Code: SYN20110410RU

• "Product E" – for treatment of growth hormone deficiency; contains a conjugate of human growth hormone and polysialic acid as the active ingredient.
  Code: SYN20100504RU

Histone

• "Product F" – for treatment of hematological malignancies, Acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL); contains histone H1.3 as the active ingredient.
  Code: SYN20051604RU
  Code: SYN20051504RU

• "Product G" – for treatment of peripheral vascular disease; contains histone H1.3 and kambiogenplasmid as the active ingredients.
  Code: SYN20112312RU

• "Product H" – for treatment of atherosclerosis; contains histone H1.3 and siRNA apoВ100 as the active ingredients.
  Code: SYN20110119RU

Gemacell

• "Product I" – for treatment of chronic diffuse liver disease; contains haematopoietic stem cells stem cells as its active ingredient.
  Code: SYN20092304RU